  ABSTRACT
In patients with diabetes, a complex and controversial relationship exists between intensive glycemic control and cardiovascular (CV) outcomes. Although the value of glucose-lowering agents in preventing microvascular complications associated with diabetes has been established, along with reductions in ischemic coronary events, active treatment in one major glycemic-control trial resulted in an unexplained increase in CV-associated mortality and total deaths compared with controls. Questions of CV safety with specifi c glucose-lowering agents along with the mechanisms underlying their effects on CV events have not been fully answered, underscoring the need for additional well-designed, long-term randomized controlled trials (RCTs) to prove their CV safety vs an active comparator. The CV benefi ts of one sodium-glucose cotransporter-2 inhibitor reported in an RCT await confi rmation in ongoing trials.
  KEY POINTS
Long-term randomized controlled trials have established the value of intensive glycemic control in reducing CV outcomes in patients with type 2 but only after many years of follow-up.
Despite reductions in ischemic coronary events, some clinical trials have reported unexplained increases in CVassociated mortality and total deaths in patients receiving intensive glycemic control.
Trials reporting the impact of specifi c glucose-lowering agents on CV events have reported perplexing, sometimes contradictory results, underscoring the need for additional trials.
T he essential value of glycemic control in preventing microvascular and neuropathic complications was established in the Diabetes Control and Complications Trial (DCCT) 1 and the United Kingdom Prospective Diabetes Study (UKPDS), 2 conducted in patients with type 1 and type 2 diabetes, respectively. However, it took another 10 or more years of observational follow-up of those cohorts to demonstrate statistically signifi cant atherosclerotic cardiovascular (CV) disease benefi ts resulting from the intensive glycemic control achieved during those trials, as reported in the DCCT-Epidemiology of Diabetes Interventions and Complications (EDIC) 3 and the UKPDS follow-up studies. 4 Overall, it took more than 20 years of observational follow-up of the original intensive glucose-treatment cohort of DCCT/ EDIC to show a signifi cant decline in total deaths compared with the conventional treatment cohort. 5 In patients with type 2 diabetes, the relationship between intensive glycemic control and CV benefi ts is somewhat controversial, particularly in view of negative CV outcomes from several long-term clinical trials in subjects older than the UKPDS subjects and with longer duration of diabetes:
• ACCORD trial (Action to Control Cardiovascular Risk in Diabetes) 6, 7 • ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modifi ed Release Controlled Evaluation) 8, 9 • VADT: (Veteran Affairs Diabetes Trial).
10,11
The controversy was spurred by an unexplained increase in total deaths in ACCORD, 6 ,7 despite a reduction in ischemic coronary events. In the VADT, 10,11 a signifi cant decline was reported for major CV events, but not total deaths, after a median of 9.8 years of observational follow-up. 11 In the ADVANCE cohort, 8, 9 a reduction in total deaths or CV events was not seen after 5.4 years of additional follow-up.
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patients in the UKPDS population, and differences in specifi c glucose-lowering strategies. Nevertheless, this remains an unsettled issue.
   CV OUTCOMES WITH SPECIFIC
ANTIHYPERGLYCEMIC AGENTS Another poorly understood question relates to the impact of specifi c glucose-lowering agents on CV events, regardless of the glucose control. Table 1 lists the studies of the currently available agents. Studies such as the UKPDS have investigated the question of intensive hyperglycemia control compared with standard, less intensive control.
The question of CV safety with glucose-lowering agents was highlighted in a 2007 meta-analysis of 42 short-term studies with rosiglitazone that reported signifi cantly worse myocardial infarction (MI) risks along with increased mortality from all CV causes that was borderline signifi cant (P = .06). 12 This fi nding, however, was not confi rmed in the only randomized controlled trial (RCT) completed with rosiglitazone. 13 The controversy led the US Food and In the UKPDS, the only primary prevention trial thus far, investigators used fi rst-generation sulfonylureas (glyburide and chlorpropamide) with or without insulin as the intensive control strategy in 3,867 patients newly diagnosed with type 2 diabetes.
2 After a median follow-up of 10 years, the active treatment group had a borderline benefi t in fatal and nonfatal MI (16% reduction in relative risk for MI; P = .052) compared with the nondrug treatment.
Additionally, a small subgroup of overweight patients in the UKPDS who were randomized to metformin (N = 342) had 36% (P = .010) lower risk of all-cause mortality and 39% (P = .011) lower risk of MI compared with conventional treatment. 15 This benefi t occurred despite a more modest hemoglobin A1c (HbA1c) reduction (0.6%) in the metformin group than in the entire UKPDS trial (0.9%).
The mechanism underlying these impressive CV benefi ts remains unclear in view of the nonglucose effects of metformin, such as lack of weight gain. Metformin also has been reported to reduce generation of advanced glycosylation end products and oxidative damage to apolipoprotein B100 in patients with type 2 diabetes. 16 One curious but unexplained fi nding in the UKPDS was an increase in both diabetes-related deaths (relative risk [RR], 1.96; P = .039) and total deaths (RR, 1.60; P = .04) in a subgroup of 268 patients in whom metformin was added to sulfonylurea therapy; however, the number of total deaths was relatively small, 47 deaths in the metformin added group and 31 deaths in the sulfonylurea group. 15 Because of the absence of proven CV benefi ts with any other diabetes drug thus far, metformin is generally the preferred initial drug in all treatment guidelines.
The relative effects of metformin and sulfonylureas when used as the initial monotherapy regimen have been studied in several large observational studies. [17] [18] [19] [20] In general, there appears to be a consistent pattern of signifi cantly increased CV events and total mortality-by 20% to 50%-in those treated with sulfonylureas, with or without prior CV disease. However, these analyses were not based on RCTs.
In two RCTs-NAVIGATOR Study Group 21 and STOP-NIDDM Trial
22
-patients with impaired Saxagliptin (SAVOR-TIMI 53) 31, 33 Sitagliptin (TECOS) 32 GLP-1 receptor agonists Lixisenatide (ELIXA) 40 SGLT-2 inhibitors (EMPA-REG OUTCOME trial) 43 Insulin (DIGAMI-1, DIGAMI-2) [44] [45] [46] (HI-5) 47 Prandial vs basal insulin (HEART2D) 48, 49 Basal insulin (ORIGIN) 50 DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; SGLT-2 = sodium-glucose cotransporter-2.
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GANDA glucose tolerance were recruited with the primary aim of preventing progression to diabetes. In the NAVIGATOR trial, the short-acting insulin secretagogue nateglinide did not reduce CV events or the progression to diabetes. 21 In the other study, acarbose, an alpha-glucosidase inhibitor, signifi cantly reduced CV events (hazard ratio [HR], 0.51; 95% confi dence interval [CI], 0.28-0.85; P = .03) 22 and also prevented progression to diabetes. (P < .002). 23 Although the number of CV events in that 3-year study was small, a meta-analyses of seven studies using acarbose therapy in patients with diabetes also found a signifi cant reduction in composite CV events (HR, 0.65; P < .007), including MIs. 24 A long-term, much larger RCT with acarbose is in progress. 25 Following the demonstration of strikingly protective effects of metformin on CV events in the UKPDS, 16 two major trials of thiazolidinediones (TZDs) investigated the effects of insulin sensitization on CV events. 13, 26 Pioglitazone in patients with long duration type 2 diabetes mellitus and pre-existing CV disease was reported to marginally reduce major CV outcomes (HR, 0.84; 95% CI, 0.72-98; P < .03), 26 whereas rosiglitazone in patients with a shorter duration of diabetes was found to be noninferior to the control group. 13 In both trials, however, there was a twofold increased risk for hospitalization for heart failure and increased risk for bone fractures in women, 13, 26 but without an increased risk for mortality. 27 Furthermore, in the BARI 2D trial in patients with diabetes and established CV disease, adding rosiglitazone did not signifi cantly reduce propensity-matched CV outcomes, compared with insulin secretagogues or insulin. 28 Thus, while TZDs appear to have no major adverse effects on CV outcomes, the other associated adverse effects limit their use.
In a 1-year study of the effi cacy and CV safety of the dopaminergic agent quick-release bromocriptine, an FDA-approved drug for diabetes, there was a marked decrease in incidence of composite CV end points (HR, 0.60; 95% CI, 0.37-0.96). 29 However, there also was a 47% dropout rate and a small number of total events; thus, the implications remain inconclusive.
Incretin-mimetic agents and CV outcomes
Following the FDA guidance, 14 all newer agents, including incretin-mimetic agents (dipeptidyl peptidase-4 [DPP-4] inhibitors and glucagon-like peptide-1 [GLP-1] receptor agonists) and sodiumglucose cotransporter-2 (SGLT-2) inhibitors have been undergoing well-designed, long-term, noninferiority trials with the comparison group receiving the standard of diabetes and CV care. The goal of these trials, unlike that of most of the studies discussed in this article, was to investigate the safety of individual agents rather than different levels of glycemic control.
Since 2013, such trials with three of the available DPP-4 inhibitors have been completed ( Table 2) . [30] [31] [32] [33] [34] Each trial was conducted in patients with pre-existing CV disease or high risk of it. The mean duration of follow-up in these trials was 1.5 to 3.0 years. There were signifi cant, but only marginal, differences in HbA1c compared with the control groups receiving standard care. In each trial, the primary CV end points showed noninferiority, thus documenting their CV safety. One important difference in secondary end points was a signifi cant increase in hospitalization rates for heart failure with saxagliptin 31,33 that was not observed in the trials with alogliptin 30, 34 or sitagliptin. 32 Another secondary end point-hospitalization for heart failure plus CV mortality-also was not increased in the alogliptin 34 and sitagliptin 32 trials (rates not reported for saxagliptin); however, there was no increase in total deaths from any cause in these trials.
The mechanisms underlying the increased rates of heart failure with saxagliptin are unclear. The baseline characteristics of patients in these three trials were similar ( Table 2) . Patients with type 2 diabetes have higher rates of heart failure in general, but the effects of concomitant drug therapy on risk of heart failure, other than with TZDs, have not been well studied. In an extensive meta-analysis of 84 RTCs of various durations, the overall risk (OR) of heart failure was higher in patients treated with DPP-4 inhibitors than in those treated with placebo or active comparators (OR, 1.19; 95% CI, 1.03-1.37; P = .015), suggesting that DPP-4 inhibitors as a class could be associated with an increased risk of heart failure. 35 A casecontrol study, however, found no increase in rates of heart failure with DPP-4 inhibitors, although there were very few patients on saxagliptin. 36 Yet another large retrospective, propensity-adjusted observational analysis of more than 112,000 patients, which compared those on saxagliptin and sitagliptin, reported no difference in rates of heart failure; however, the median follow-up period was less than 6 months. 37 In comparative observational analyses, 18, 37, 38 the risks of heart failure with TZDs and sulfonylureas were increased, compared with DPP-4 inhibitors, particularly with TZDs. On the other hand, a large populationbased analysis from Italy found that DPP-4 inhibitors were associated with a propensity-matched 36% lower rate of hospitalization for heart failure compared with sulfonylureas. 39 These data point to a need for more
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well-designed comparative studies to investigate valid differences between drugs in this class.
In the only GLP-1 receptor agonist trial completed thus far, ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome), there were no differences in primary and major secondary CV outcomes in 6,068 very high-risk patients randomized to lixisenatide or placebo after a 25-month follow-up (HR, 1.02; 95%, CI, 0.89-1.17). 40 Moreover, the hospitalization rates for heart failure were not increased (HR, 0.96; 95% CI, 0.75-1.23). The earlier meta-analyses of shortterm studies with DPP-4 inhibitors reporting significant reductions in CV events 41, 42 also underscore the need for well-designed long-term RCTs to accurately interpret drug effects.
SGLT-2 inhibitors and CV outcomes
The fi rst CV outcome RCT with the SGLT-2 inhibitor empaglifl ozin, the EMPA-REG OUTCOME trial, 43 was recently reported. Of great importance in this 7,020-patient trial comparing empaglifl ozin with placebo were the following results:
• 14% reduction in the primary end point (composite of death from CV causes, nonfatal MI, or nonfatal stroke) (P = .04) • 32% reduction in all-cause deaths (P < .001) • 35% reduction in hospitalization for heart failure (P = .002). The mechanism underlying these impressive benefi ts is not known, although there were modest reductions in HbA1c levels, body weight (~2 kg), waist circumference (~2 cm), and systolic blood pressure (~4 mm Hg) with empaglifl ozin. The main adverse effects were related to a 3 to 4 times increased incidence of genital infections. Trials with other agents in this class are currently ongoing.
Insulin and CV outcomes
The UKPDS trial is the only primary prevention trial that provided evidence of signifi cant benefi ts from intensive glucose control (with insulin, with or without sulfonylurea therapy) on CV outcomes and mortality, but only after 10 additional years of follow-up after the end of the trial. 4 A few other trials have investi- 
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The DIGAMI-1 (Diabetes Insulin-Glucose in Acute Myocardial Infarction) was a RCT conducted between 1990 and 1993 in 620 patients with type 2 diabetes and acute MI randomized to short-term, intensive insulin-based glucose therapy or to conventional glucose-lowering therapy. 44 Results showed the intensive treatment group had an 11% decrease in mortality rate at 3.4 years. A 20-year follow-up reassessment showed the overall survival was improved by a mean of 2.3 years at 8 years, particularly in those at lower risk at baseline. 45 However, none of these patients were on statin therapy at baseline; thus, the implications of that study with current standards of care are quite uncertain. Subsequent studies-DIGAMI-2 (N = 1,253) 46 and the HI-5 (Hyperglycemia: Intensive Insulin Infusion in Infarction) study (N = 240), 47 both investigating the effects of intensive insulin therapy in patients with type 2 diabetes and MI-showed no signifi cant effects on mortality in patients at 1 year (DIGAMI-2) and 6 months (HI-5).
The HEART2D trial (Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus), an RCT of 1,115 post-MI patients, investigated the effects of targeting prandial insulin compared with basal insulin. During a mean follow-up of 2.7 years, there were no between-group differences in CV outcomes (HR, 0.98; 95% CI, 0.8-1.21) or glycemic control. 48 Also, there was no impact of glycemic variability. 49 Finally, the ORIGIN trial (Outcome Reduction With an Initial Glargine Intervention), an RCT of more than 12,000 patients at high risk for CV disease but with relatively recent onset of either type 2 diabetes or prediabetes, randomized patients to basal insulin glargine or noninsulin treatments. 50 The baseline HbA1c was relatively low at 6.4%, but it signifi cantly declined by 0.3% by the end of trial, compared with the control group. There was no effect on CV outcomes (HR, 1.02; 95% CI, 0.94-1.11) after a median follow-up of 6.2 years.
However, it remains a perplexing question regarding whether long-term treatment with increasing insulin dosages in a subset of obese patients with poorly controlled type 2 diabetes and increasing insulin resistance could be potentially harmful to the CV system. 51 
  CONCLUSION
The long-term RCTs with antihyperglycemic agents, including DCCT/EDIC in type 1 diabetes and UKPDS, ACCORD, and VADT in type 2 diabetes, with the exception of ADVANCE, have established the value of intensive glycemic control in reducing CV outcomes but only after many years of follow-up. However, the effects of intensive glycemic control on CV disease in type 2 diabetes are inconsistent, with only the primary prevention cohorts of UKPDS showing signifi cant effects on mortality after prolonged follow-up. This is in contrast to the positive effects of statins in relatively short-term trials.
While it is diffi cult to interpret the CV results of specifi c drugs from the degree of glycemic control, it is reassuring that the large RCTs with several individual agents, including TZDs (both pioglitazone and rosiglitazone), several DPP-4 inhibitors, and one GLP-1 receptor agonist, have demonstrated no appreciable harm. The increase in the secondary outcome of heart failure but with no increase in mortality observed with saxagliptin requires further mechanistic studies while awaiting the results of other ongoing trials with newer agents including other incretin-based drugs and SGLT-2 inhibitors.
With SGLT-2 inhibitors, the recently published results of the empaglifl ozin trail (EMPA-REG OUTCOME trial) with type 2 diabetes revealed a signifi cant reduction in CV end points and mortality. Before those data were published, metformin was the only antihyperglycemic drug that had shown a signifi cant effect on CV events and mortality, but it was studied in only a small subgroup of the UKPDS cohort, and there are no RCTs of the relative impact of metformin or other agents as compared to sulfonylureas. The results of ongoing CV trials with SGLT-2 inhibitors are eagerly awaited.
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